Morgan Stanley Analysts Give Ultragenyx Pharmaceutical (RARE) a $70.00 Price Target

Ultragenyx Pharmaceutical (NASDAQ:RARE) received a $70.00 target price from equities researchers at Morgan Stanley in a note issued to investors on Monday, The Fly reports. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential upside of 41.61% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Credit Suisse Group reduced their price objective on Ultragenyx Pharmaceutical from $78.00 to $59.00 and set a “hold” rating for the company in a research note on Monday. Wedbush upped their price objective on Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, August 6th. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. Raymond James set a $70.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Friday, October 26th. Finally, SunTrust Banks reduced their price objective on Ultragenyx Pharmaceutical from $83.00 to $54.00 and set a “buy” rating for the company in a research note on Monday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the company. Ultragenyx Pharmaceutical presently has an average rating of “Buy” and a consensus price target of $77.00.

Shares of Ultragenyx Pharmaceutical stock opened at $49.43 on Monday. The firm has a market cap of $2.44 billion, a P/E ratio of -6.59 and a beta of 1.95. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $90.98.



Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.08) by $1.02. The firm had revenue of $12.79 million during the quarter, compared to the consensus estimate of $5.63 million. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. During the same quarter in the prior year, the company earned ($1.72) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical will post -4.38 EPS for the current fiscal year.

In other news, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total transaction of $603,469.00. Following the transaction, the chief financial officer now owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William Aliski sold 3,750 shares of the company’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $76.66, for a total value of $287,475.00. Following the transaction, the director now directly owns 72,610 shares in the company, valued at approximately $5,566,282.60. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock worth $2,700,774 in the last ninety days. Insiders own 8.40% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in Ultragenyx Pharmaceutical by 162.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 72,813 shares of the biopharmaceutical company’s stock worth $5,565,000 after purchasing an additional 45,097 shares in the last quarter. First Trust Advisors LP lifted its holdings in Ultragenyx Pharmaceutical by 29.3% during the 3rd quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock worth $96,453,000 after purchasing an additional 285,961 shares in the last quarter. Capital Impact Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 6.2% during the 3rd quarter. Capital Impact Advisors LLC now owns 28,746 shares of the biopharmaceutical company’s stock worth $2,295,000 after purchasing an additional 1,672 shares in the last quarter. Northern Trust Corp lifted its holdings in Ultragenyx Pharmaceutical by 6.7% during the 2nd quarter. Northern Trust Corp now owns 554,092 shares of the biopharmaceutical company’s stock worth $42,594,000 after purchasing an additional 34,942 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Ultragenyx Pharmaceutical by 1.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 207,662 shares of the biopharmaceutical company’s stock worth $15,963,000 after purchasing an additional 3,903 shares in the last quarter. 96.12% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Read More: How accurate is the Rule of 72?

The Fly

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply